FRAXA's Impact to Date

$
0
33.6
Million

Direct Investment in Fragile X Research

0
42

TEAMS ACTIVELY RESEARCHING FRAGILE X

Current Research Grants
0
31

PHARMACEUTICAL AND BIOMEDICAL PARTNERS

0
629

RESEARCH GRANTS AWARDED

0
19

COUNTRIES ARE HOME TO RESEARCH TEAMS

What is Fragile X Syndrome?

Fragile X syndrome (FXS) is the most common inherited cause of autism and intellectual disabilities. It affects 1 in 4,000 boys and 1 in 8,000 girls worldwide.

Fragile X syndrome occurs when a single gene on the X chromosome shuts down. This gene makes a protein needed for normal brain development. In FXS it does not work properly, the protein is not made, and the brain does not develop as it should.

Learn more about Fragile X syndrome

How Does FRAXA Help?

FRAXA’s mission is to find effective treatments and ultimately a cure for Fragile X syndrome. We directly fund research grants and fellowships at top universities around the world. We partner with biomedical and pharmaceutical companies, large and small, to bridge the gap between research discoveries and actual treatments.

Treatments for Fragile X are likely to help people affected by autism, Alzheimer’s, and other brain disorders.

Donate to FRAXA's mission

Latest Fragile X News & Updates

View all News & Updates

Using Exosomes to Discover Fragile X Biomarkers

Exosomes as a Source of Therapeutic Biomarkers in Experimental Models of Fragile X Syndrome Alberto Martire, PhD Principal Investigator Zaira Boussadia, PhD FRAXA Fellow Italian National Institute of Health Rome, Italy 2023-2024 Grant Funding: $100,000 Summary How can a blood
Read more

FRAXA Investigator Lynne Maquat Awarded 2023 Gruber Genetics Prize

Dr. Maquat, 2023 Gruber Genetics Prize winner, discovered NMD, a key surveillance system in the body that protects against mistakes in gene expression. Her groundbreaking research has led to new therapies for Fragile X syndrome.
Read more

Coming Together for Rare Disease Day 2023

Today, February 28, we mark Rare Disease Day, a day dedicated to raising awareness about rare diseases and highlighting the need for continued research and collaboration. At FRAXA Research Foundation, we are committed to advancing research on Fragile X syndrome, one of the most common rare diseases worldwide.
Read more

Recruiting: Tetra Therapeutics Initiates Phase 2B/3 Clinical Studies in Fragile X Syndrome

Tetra Therapeutics has launched large scale clinical trials of their phosphodiesterase (PDE) inhibitor for males ages 12-45 with Fragile X syndrome. FRAXA Research Foundation's basic and translational research pointed the way to phosphodiesterase inhibitors to treat Fragile X.
Read more

Sex-specific Learning Differences Found in Fragile X Patients, Mouse Model

Girls and women with Fragile X syndrome show different learning impairments relative to boys and men with the disease, a finding that was paralleled in a mouse model of the disease, a study found.
Read more

Targeting Cognitive Function in Fragile X Syndrome

It has long been assumed that the differences between males and females with Fragile X were simply a matter of degree, with males being more severely affected. But gender differences may be far reaching. This team is working to understand imbalances in how the brain's neurons transmit signals, with a focus on how differently males and females learn and experience anxiety. They are studying two neuronal pathways which are promising targets for treatment.
Read more